A5024334193- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cytomegalovirus and herpesvirus research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Venous Thromboembolism Diagnosis and Management
- Platelet Disorders and Treatments
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- Transplantation: Methods and Outcomes
- Cardiac Arrest and Resuscitation
- Herpesvirus Infections and Treatments
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Hemoglobinopathies and Related Disorders
- Respiratory viral infections research
- Complement system in diseases
- Blood disorders and treatments
- Cerebrospinal fluid and hydrocephalus
- Chronic Lymphocytic Leukemia Research
- Neurological Complications and Syndromes
- Respiratory Support and Mechanisms
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Virus-based gene therapy research
Fred Hutch Cancer Center
2016-2025
Griffith University
2024
University of Washington
1997-2017
University of Colorado Denver
2009
Denver Health Medical Center
2009
Prince Charles Hospital
2009
Cancer Research Center
2003
University of Pennsylvania
2001
Cleveland Clinic
1994
Washington University in St. Louis
1994
The impact of cytomegalovirus (CMV) serostatus (seropositive [+] or seronegative [-]) the donor (D) and recipient (R) on mortality after allogeneic non-T cell-depleted stem cell transplantation (SCT) in era preemptive therapy was assessed among 1750 patients by means multivariable Cox regression models. In an analysis that included only pre-SCT variables, D+/R+ D+/R- had highest risk for mortality. After neutropenia occurrence CMV disease controlled for, remained at a significantly higher...
PURPOSE We designed and conducted a randomized single-institution trial comparing two common prophylactic platelet transfusion thresholds in patients undergoing induction therapy for acute leukemia. PATIENTS AND METHODS Seventy-eight leukemia were to receive apheresis concentrates when the count was either < or = 10,000/microL 20,000/microL. RESULTS There no significant difference total number of bleeding episodes per patient with median four arm 20,000/microL (25th 75th percentiles 2, 7...
Adenoviruses (ADV) are emerging as important causes of morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). In mainly non-T-cell depleted HSCT recipients, we analyzed the incidence ADV infection, risk factors for effect ganciclovir administered prevention cytomegalovirus (CMV), impact infection on survival. The overall ADV, irrespective method detection, was 8.5% (450/5233) 12.3% (43/348) after first or second allogeneic HSCT, 6.3% (78/1219) 6.5%...
Transplant-associated thrombotic microangiopathy (TA-TMA) after allogeneic hematopoietic cell transplantation (HCT) has not been well characterized in large population studies with clinically adjudicated cases. We performed a retrospective cohort study of adults who underwent HCT between 2006 and 2015 to determine the incidence risk factors for TA-TMA describe its natural history response immunosuppressant withdrawal management. Among 2145 patients this study, 192 developed cumulative 7.6%...
After primary recovery of platelet counts after transplantation, there can be a late persistent decline called secondary failure (SFPR), which may occur although the other cell lineages remain within normal range. SFPR was defined as below 20,000/microL for 7 consecutive days or requiring transfusion support achieving sustained > = 50,000/microL without transfusions hematopoietic stem transplantation (HSCT). The study population consisted 2871 patients receiving transplants from January 1990...
Preoperative chemoradiotherapy followed by radical surgical resection has been the preferred treatment for patients presenting with locally advanced distal rectal carcinoma at our institutions. We postulated that chemoradiotherapy-induced pathologic response of primary tumor would identify which be candidates local excision as definitive therapy.A retrospective analysis 60 palpable, advanced, adenocarcinomas treated from 1995 to 2000 was performed. All received preoperative consisting...
Nonmyeloablative conditioning is less toxic and results in initial establishment of mixed hematopoietic T cell chimerism for up to half a year with prolonged presence host immunity. In this study, we examined whether translates into differences the risks and/or severity cytomegalovirus (CMV) infection disease. We analyzed data from 537 nonmyeloablative (NM-HCT) contemporaneous 2489 myeloablative transplant (M-HCT) recipients. CMV seropositive recipients, no difference overall hazards at any...
The toxicity and efficacy of dapsone given daily as Pneumocystis jiroveci (PCP) prophylaxis in hematopoietic stem cell transplant (HSCT) recipients who cannot take trimethoprim-sulfamethoxazole (TMP-SMX) have not been fully evaluated. We compared 155 HSCT received second-line PCP with 310 matched control patients TMP-SMX throughout the posttransplantation course. Among started before transplantation because allergy, there was no difference transfusion requirement after when controls....
Highlights•Herpes zoster occurred in 21% of autologous transplant recipients over 5 years•Acyclovir or valacyclovir prophylaxis were protective for herpes when use•Durable strategies are needed to prevent after transplantationAbstractThe epidemiology (HZ) contemporary hematopoietic cell (HCT) recipients, and the impact acyclovir (ACV)/valacyclovir (VACV) prophylaxis, is not well described. In this observational study from 2002 2010, we retrospectively identified 1000 varicella virus...
How conditioning intensity is related to outcomes of AML patients undergoing allografting in morphologic remission an area great ongoing interest. We studied 743 and known pre-transplant measurable residual disease (MRD) status determined by multiparameter flow cytometry (MFC) who received a first allograft after myeloablative, reduced intensity, or nonmyeloablative (MAC, RIC, NMA). Overall, relapse-free survival (RFS) overall (OS) were longer MAC than RIC NMA conditioning, whereas relapse...
Thrombocytopenia after hematopoietic stem cell transplantation (HSCT) is associated with an increased risk of bleeding and utilization significant resources. This review presents analysis factors delayed platelet engraftment. The retrospective included 1,468 recipients autologous or allogeneic transplants treated between January 1, 1990 July 1995. Risk engraftment HSCT use marrow rather than peripheral blood as the source cells, being transplanted for acute myeloid leukemia other diseases,...
Abstract Patients with hematological malignancies who survive the first year after allogeneic stem cell transplantation (allo-SCT) without relapse have a substantial risk of nonrelapse mortality (NRM) and missing predictive markers. The Endothelial Activation Stress Index (EASIX) predicts endothelial complications NRM early allo-SCT. We hypothesized that EASIX assessed 1 allo-SCT in survivors were disease free may predict late NRM. Survivors relapse-free at retrospectively studied 2...
Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (allo-HCT) is often diagnosed at a late stage when lung dysfunction severe and irreversible. Identifying patients early may offer improved strategies for detection that could avert the morbidity mortality of BOS. This study aimed to determine whether decline in function before (days +80 +100) allo-HCT are associated with risk BOS beyond 6 months post-transplantation. In single-center cohort 2941...
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a complication of allogeneic hematopoietic cell transplantation (HCT) that often occurs following the development acute graft-versus-host disease (aGVHD). In this study, we aimed to identify early TMA biomarkers among patients with aGVHD. We performed nested-case-control study from prospective cohort HCT recipients, matching on timing and severity antecedent identified 13 cases 25 non-TMA controls 208 in cohort. Using...
Abstract Venous thromboembolism (VTE) after allogeneic hematopoietic cell transplantation (HCT) is a significant treatment-associated complication, although optimal timing of thromboprophylaxis remains uncertain when weighing concurrent risks bleeding. We aimed to derive and internally validate risk assessment model (RAM) using patients who underwent first HCT from 2006 through 2015 (n = 1703). Index date was defined as the 30th day transplant, at which point we estimated &gt;75% would...